All relevant data are within the paper.

Introduction {#sec001}
============

Methylated-CpG binding protein 2 (MeCP2) is a nuclear protein encoded by the X-linked *MECP2* gene (OMIM\*300005). MeCP2 can be defined as a multifunctional protein, due to its involvement in chromatin architecture, regulation of RNA splicing, and its role both as transcriptional repressor or activator \[[@pone.0150101.ref001]\]. *MECP2* appears to be universally expressed in all cell types with few exceptions, including microglia and rod photoreceptors \[[@pone.0150101.ref002]\]. Loss-of-function mutations in *MECP2* is the main cause of Rett syndrome (RTT), which is a neurodevelopmental disease with severe cognitive impairment occurring at a ratio of approximately 1:10,000 girls \[[@pone.0150101.ref003],[@pone.0150101.ref004]\].

However, RTT is not the only known pathological condition related to *MECP2* mutations, as a wide series of conditions, collectively termed as *MECP2*-related disorders \[[@pone.0150101.ref005]\], has been reported. These disorders include asymptomatic female carriers, boys with *MECP2* mutations typically causing a RTT phenotype in girls, and rare individuals with mutations in *MECP2* showing other neurodevelopmental disorders \[[@pone.0150101.ref005]\]. Interestingly, intellectual disability (ID) is a common feature between RTT as well as *MECP2*-related disorders. Gain-of-function mutations in relation to *MECP2* also lead to a severe neurodevelopmental disorder, named *MECP2* duplication syndrome (MDS) or *MECP2* triplication syndrome \[[@pone.0150101.ref006]--[@pone.0150101.ref008]\]. The phenotypes include major cognitive and motor deficits, stunted motor development, early onset hypotonia, epilepsy, and progressive spasticity, clinical features which are overlapping with some of those seen in RTT \[[@pone.0150101.ref006],[@pone.0150101.ref007]\].

Although the prevalence of MDS is unknown, it has been estimated that MDS could be responsible for 1 to 2% of all X-linked ID cases \[[@pone.0150101.ref009]\]. MDS is well documented in males, with 150 affected individuals reported in the literature, while it rarely occurs in females \[[@pone.0150101.ref009]\], as female carriers of *MECP2*/Xq28 duplications are almost always asymptomatic due to extremely skewed X-inactivation \[[@pone.0150101.ref009]\]. This is in contrast to females with classical RTT harboring a loss-of-function mutations of the *MECP2* \[[@pone.0150101.ref010],[@pone.0150101.ref011]\].

Interestingly, a genotype-phenotype correlation in relation to the size of the Xq28 duplicated region has emerged. The minimal region of duplication that is sufficient to cause the core MDS phenotype involves the *MECP2* and *IRAK1* \[[@pone.0150101.ref012]--[@pone.0150101.ref014]\]. Evaluating previously data and data from mouse models, Ramocki and colleagues posit that *MECP2* is the primary dosage-sensitive gene responsible for the neurological phenotypes in the Xq28 duplications \[[@pone.0150101.ref007]\].

Overall, MeCP2 appears to play a key role in the brain as a regulator of synaptic and neuronal plasticity as well as an etiological role in the development of RTT and MDS \[[@pone.0150101.ref015]\].

Oxidative stress (OS) is a nonspecific pathological condition that has frequently been associated with neurological disorders, including several diseases linked to cognitive impairment \[[@pone.0150101.ref016]\]. Compelling evidence between *MECP2* loss-of-function and aberrant redox homeostasis has been shown by our and other research groups \[[@pone.0150101.ref017],[@pone.0150101.ref018]\]. Specifically, a cause-effect relationship between oxidative brain damage and *Mecp2* loss-of-function has been reported by our group in several murine models of the disease \[[@pone.0150101.ref019]\].

Since both a critical role for *MECP2* in central nervous system integrity \[[@pone.0150101.ref020]\], and an involvement of OS in brain synaptic plasticity have been reported \[[@pone.0150101.ref021]--[@pone.0150101.ref023]\], MDS can represent a clinical model for testing the hypothesis that a finely tuned balance of *MECP2* expression is critical to the control of redox homeostasis. We hypothesize that overexpression of *MECP2* would lead to a status of enhanced OS.

Materials and Methods {#sec002}
=====================

Subjects {#sec003}
--------

The study included a total of 42 subjects. Six subjects carrying an Xq28 duplication/triplication (ranging from 0.426 to 3.9 Mb) all-encompassing *MECP2* (female n = 1, males n = 5; mean age 10.7 ± 4.3 years, range: 2.5--14) were enrolled in the study. One patient (case \#6) was admitted at the Danish Epilepsy Centre, Dianalund, Denmark, while five patients (cases \#1--5) were followed at the Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena Italy. For comparative purpose, "positive" controls (RTT patients with proven *MECP2* loss-of-function mutations; n = 24; all females; mean age 10.1 ± 3.3 years, range 3--14) were also analyzed, as a part of cohort of patients on regular follow-up at the Child Neuropsychiatry Unit, University Hospital, Siena Italy. All the RTT patients were identified with a *MECP2* mutation and clinically evaluated according to the revised diagnostic criteria by Neul et al. \[[@pone.0150101.ref024]\]. The patients were all diagnosed with the classical form of RTT \[[@pone.0150101.ref004]\]. In addition, "negative" controls were newly recruited (healthy subjects n = 12; males 4, females 8; mean age 10.3 ± 3.7 years, range 3--14). Age differences were not statistically significant (P = 0.927).

The work was carried out in accordance to the rules expressed in the Declaration of Helsinki, and written informed consent was obtained by the parents of the enrolled subjects. This study was approved by the competent institutions: Ethics Committee of Western Zealand, Denmark (for the patient admitted at the Danish Epilepsy Centre), and Ethics Committee of the Tuscan Region, Azienda Ospedaliera Universitaria Senese, Siena, Italy (for the subjects recruited at the Child Neuropsychiatry Unit).

Microarray-comparative genomic hybridisation (array-CGH) analysis {#sec004}
-----------------------------------------------------------------

The Xq28 duplications were identified by Array-CGH analysis using Agilent oligonucleotide array kit 44B (Human Genome CGH Microarray Kit 44B; Agilent Technologies, Santa Clara, CA), with an average resolution of about 75 kb or by a sub-megabase resolution whole genome tiling path BAC array (<http://www.molgen.mpg.de/~abt_rop/molecular_cytogenetics/>). The duplications were confirmed by real-time quantitative polymerase chain reaction (qPCR) \[[@pone.0150101.ref025]\].

Blood sampling {#sec005}
--------------

Blood sampling was carried out after the overnight fast. Blood samples were collected in heparinized tubes, and centrifuged at 2,400Xg for 15 min at room temperature. The platelet poor plasma was saved, and the buffy coat was removed by aspiration. Erythrocytes were washed twice with physiological solution, suspended in Ringer solution, pH 7.4 as a 50% (vol/vol) suspension, and then used for the determination of intraerythrocyte non-protein bound iron (IE-NPBI). Plasma was used for free F~2~-isoprostanes (F~2~-IsoPs), F~4~-neuroprostanes (F~4~-NeuroPs), F~2~-dihomo-isoprostanes (F~2~-dihomo-IsoPs), and plasma non-protein bound iron (p-NPBI). For all isoprostane determinations, butylated hydroxytoluene (BHT) (90 μM) was added to plasma as an antioxidant.

Oxidative stress marker evaluations {#sec006}
-----------------------------------

The examined markers included non-protein bound iron (NPBI) (pro-oxidant factor), F~2~-IsoPs (the oxidized products from arachidonic acid and markers of OS/systemic lipoperoxidation), F~4~-NeuroPs (the oxidized products from docosahexaenoic acid and markers of neuronal membrane damage/brain gray matter), and F~2~-dihomo-IsoPs (the oxidized products from adrenic acid and markers of glia membrane damage/brain white matter) \[[@pone.0150101.ref017]\]. OS markers were measured as previously reported. Briefly, IE-NPBI and p-NPBI were determined as a desferrioxamine-iron complex by high-performance liquid chromatography \[[@pone.0150101.ref026]\], whereas F~2~-IsoPs, F~4~-NeuroPs, and F~2~-dihomo-IsoPs were determined by a gas chromatography/negative ion chemical ionization tandem mass spectrometry (GC/NICI-MS/MS) analysis \[[@pone.0150101.ref026]--[@pone.0150101.ref028]\].

Routine blood tests {#sec007}
-------------------

Serum concentrations of total cholesterol, high density lipoproteins (HDL)-cholesterol, triglycerides, immunoglobulin class G, class A and class M (IgG, IgA, IgM), were performed by a fully automatic analyzer (Cobas 6000 System; Roche Diagnostics). Total cholesterol, HDL-cholesterol, and triglycerides were assayed by using an enzymatic methods \[[@pone.0150101.ref029]--[@pone.0150101.ref031]\]. Serum fibrinogen concentration was determined by using Thromborel Reagent on BCS XP coagulation analyzer (Siemens Healthcare) \[[@pone.0150101.ref032]\]. Erythrocyte Sedimentation Rate (ESR) was assayed by using an automated system \[[@pone.0150101.ref033]\]. Blood cells counts were assayed on Sysmex XT-2100 system \[[@pone.0150101.ref034]\].

Data analysis {#sec008}
-------------

All variables were tested for normal distribution (D'Agostino-Pearson test). Differences between groups were evaluated by either one-way analysis of variance (ANOVA), or the Kruskal--Wallis test, as appropriate. Associations between variables were tested using linear regression analyses (for continuous normally distributed data) or the Spearman rank correlation (for continuous non normally distributed variables). A two-tailed P \< 0.05 was considered to indicate statistical significance. The MedCalc ver. 12.0 statistical software package (MedCalc. Software, Mariakerke, Belgium) was used for data analysis.

Results {#sec009}
=======

All the enrolled patients showed a *MECP2* duplication/triplication whose position and size was defined according to the GRCh37/hg19 human genome annotation ([Fig 1](#pone.0150101.g001){ref-type="fig"} and [Table 1](#pone.0150101.t001){ref-type="table"}).

![Graphical view of the *MECP2* duplications/triplication.\
Graphical view of the *MECP2* duplications/triplication was created with custom tracks in the UCSC genome browser (GRCh37/hg19), (Patient 1 was identified with a triplication). The involved regions are shown in blue and *MECP2* is marked by a red circle.](pone.0150101.g001){#pone.0150101.g001}

10.1371/journal.pone.0150101.t001

###### *MECP2* duplication syndrome: clinical features and genetic details.

![](pone.0150101.t001){#pone.0150101.t001g}

  Clinical features                                                                                      Patient \#1                                                             Patient \#2                                                                                                                                            Patient \#3                                                                                                                                               Patient \#4                                  Patient \#5                                 Patient \#6
  ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------
  Age (years)                                                                                            14                                                                      8                                                                                                                                                      2.5                                                                                                                                                       9                                            13                                          12
  Gender                                                                                                 Male                                                                    Female                                                                                                                                                 Male                                                                                                                                                      Male                                         Male                                        Male
  Microcephaly                                                                                           Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     No
  Hand stereotypies                                                                                      Yes (++)                                                                Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (++)                                     Yes (+)                                     No
  Abnormal breathing                                                                                     Yes (+)                                                                 Yes (+)                                                                                                                                                No                                                                                                                                                        Yes (+)                                      Yes (+)                                     No
  Bruxism                                                                                                Yes (++)                                                                Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (++)                                     Yes (+)                                     No
  Laryngomalacia                                                                                         Yes                                                                     No                                                                                                                                                     Yes                                                                                                                                                       No                                           No                                          No
  Sleep disturbances                                                                                     Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     Yes (+++)
  GERD, drooling                                                                                         Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     Yes (+)
  Constipation                                                                                           Yes (++)                                                                Yes (++)                                                                                                                                               Yes (++)                                                                                                                                                  Yes (+++)                                    Yes (++)                                    Yes (++)
  Genital abnormalities                                                                                  No                                                                      No                                                                                                                                                     No                                                                                                                                                        Yes (hypospadias)                            No                                          No
  Facial dysmorphism                                                                                     Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     No
  Facial hypotonia                                                                                       Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     Yes (+)
  Dysphagia                                                                                              Yes (+++)                                                               Yes (++)                                                                                                                                               No                                                                                                                                                        Yes (+++)                                    Yes (++)                                    Yes (+)
  Intellectual Disability                                                                                Yes (+++)                                                               Yes (+++)                                                                                                                                              Yes (+++)                                                                                                                                                 Yes (+++)                                    Yes (+++)                                   Yes (+++)
  Developmental regression                                                                               Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     Yes (+)
  Epilepsy                                                                                               Yes (+++)                                                               Yes (+++)                                                                                                                                              No                                                                                                                                                        Yes (+++)                                    Yes (+++)                                   Yes (+++)
  MRI abnormalities                                                                                      Yes[\*](#t001fn002){ref-type="table-fn"}                                Yes[\*](#t001fn002){ref-type="table-fn"}[†](#t001fn004){ref-type="table-fn"}[¶](#t001fn005){ref-type="table-fn"}[‡](#t001fn006){ref-type="table-fn"}   Yes[\*](#t001fn002){ref-type="table-fn"}[¶](#t001fn005){ref-type="table-fn"}[‡](#t001fn006){ref-type="table-fn"}[\*\*](#t001fn003){ref-type="table-fn"}   Yes[\*\*](#t001fn003){ref-type="table-fn"}   Yes[\*](#t001fn002){ref-type="table-fn"}    Yes[\*](#t001fn002){ref-type="table-fn"}
  Hypotonia/ spasticity                                                                                  Yes (+++)                                                               Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+++)                                   Yes
  Feeding difficulties                                                                                   Yes (+)                                                                 Yes (+)                                                                                                                                                Yes (+)                                                                                                                                                   Yes (+)                                      Yes (+)                                     Yes
  Recurrent Infections                                                                                   Yes[^§^](#t001fn007){ref-type="table-fn"}                               No                                                                                                                                                     Yes[^§^](#t001fn007){ref-type="table-fn"}                                                                                                                 Yes[^§^](#t001fn007){ref-type="table-fn"}    Yes[^§^](#t001fn007){ref-type="table-fn"}   Yes
  Endocrine abnormalities                                                                                No                                                                      Yes (hypothyroidism)                                                                                                                                   No                                                                                                                                                        No                                           No                                          No
  *MECP2* duplication/triplication[•](#t001fn008){ref-type="table-fn"} position and size (GRCh37/hg19)   chrX:151198447--155190224[•](#t001fn008){ref-type="table-fn"} (\~4Mb)   chrX:152370000--153410000 (1Mb)                                                                                                                        chrX:153049224--153877929 (\~828kb)                                                                                                                       chrX: 153101077--153713921 (\~613kb)         chrX: 153043806--154294453 (\~1,2Mb)        chrX: 152982000--153408000 (\~426kb)

Yes (+++), Yes (++), and Yes (+) indicated high, medium, and low relevance of the clinical presentation, respectively.

\*Central and cortical atrophy

\*\*Periventricular leukomalacia

†immature white matter features, mainly involving frontal lobe

¶Cavum vergae

‡Cyst of the septum pellucidum

^§^recurrent upper and lower respiratory tract infections.

•Patient with *MECP2* triplication, GERD; gastro esophageal reflux disease, MRI; magnetic resonance imaging, Mb; mega base, kb; kilo base.

The typical features of the MDS, including developmental regression, epilepsy, magnetic resonance imaging abnormalities, hypotonia/spasticity were present in all the examined patients with the single exception of epilepsy, reported in five out of six subjects ([Table 1](#pone.0150101.t001){ref-type="table"}).

All the MDS patients showed relevant differences in four out of five of the investigated OS markers, as compared to the healthy controls ([Fig 2](#pone.0150101.g002){ref-type="fig"}). In particular, significantly increased plasma levels of p-NPBI and IE-NPBI, forms of redox active iron, and both F~2~-IsoPs and F~4~-NeuroPs, non-enzymatic oxidized products from polyunsaturated fatty acids (i.e., arachidonic and docosahexaenoic acid, respectively), were detected. No significant differences were evidenced for F~2~-dihomo-IsoPs, biomarkers of adrenic acid oxidation. Both examined forms of iron (i.e., p-NPBI and IE-NPBI) are considered pro-oxidant agents \[[@pone.0150101.ref026]\], whereas the investigated isoprostanoids are indexes of lipid peroxidation (i.e., F~2~-IsoPs) \[[@pone.0150101.ref026]\], and brain gray (i.e., F~4~-NeuroPs) or white (i.e., F~2~-dihomo-IsoPs) matter oxidative damage \[[@pone.0150101.ref027], [@pone.0150101.ref028]\].

![Oxidative stress marker plasma levels in MDS and RTT.\
Levels of NPBI, plasma free F~2~-IsoPs, F~4~-NeuroPs, and F~2~-dihomo-IsoPs in MDS are compared with those of RTT and healthy control subjects. All the statistical significant differences were reported. Legend: ANOVA, analysis of variance; F~2~-dihomo-isoPs, F~2~-dihomo-isoprostanes; F~2~-IsoPs, F~2~-isoprostanes; F~4~-NeuroPs, F~4~-neuroprostanes; IE-NPBI, intraerythrocyte non protein bound iron; MDS, *MECP2* Duplication Syndrome; p-NPBI, plasma non protein bound; RTT, Rett syndrome.](pone.0150101.g002){#pone.0150101.g002}

A comparison of the OS status in MDS patients and RTT patients *vs* the healthy control population evidenced similarities, with the exceptions of significantly higher plasma levels of F~2~-IsoPs and lower plasma levels of F~2~-dihomo-IsoPs in MDS. Indeed, the levels of p-NPBI, IE-NPBI, and F~4~-NeuroPs in MDS were found to be comparable to those observed in RTT ([Fig 2](#pone.0150101.g002){ref-type="fig"}). Moreover, the levels of all the examined plasma and intraerythrocyte biomarkers were significantly higher in RTT as compared to the control group ([Fig 2](#pone.0150101.g002){ref-type="fig"}).

A significant positive correlation between the Xq28 region duplication/triplication size and plasma levels of F~2~-IsoPs (r = 0.9181; 95% C.I.: 0.4181 to 0.9912; P = 0.0098) was evidenced ([Fig 3](#pone.0150101.g003){ref-type="fig"}). Additionally, a correlation trend between the Xq28 region duplication size and the erythrocyte sedimentation rate (ESR) (r = 0.732; P = 0.1598) was observed. On the other hand, no significant correlations were detected between OS markers and age, thus reinforcing the hypothesis of a link between the *MECP2* gain-of-function mutations and OS derangement.

![Relationship between plasma F~2~-IsoPs and Xq28 size (univariate regression analysis).\
A positive linear relationship of plasma F~2~-IsoPs vs. Xq28 duplication/triplication size is showed. The strength of the relationship is indicated by the correlation coefficient (r = 0.9181, P = 0.0098). The linear regression equation was reported.](pone.0150101.g003){#pone.0150101.g003}

Significant differences were observed for total cholesterol, ESR, and ALC (post-hoc comparison: RTT \> MDS ≈ Control Subjects; MDS ≈ RTT \> Control Subjects; MDS ≈ RTT \> Control Subjects, respectively) ([Table 2](#pone.0150101.t002){ref-type="table"}). In contrast, no significant differences were reported for all the other parameters of the typical clinical-chemical pattern ([Table 2](#pone.0150101.t002){ref-type="table"}). No significant differences were present for immunoglobulin class G and class M, high density lipoproteins-cholesterol, white blood cells, absolute counts for neutrophils, eosinophils, or basophils. (data not shown).

10.1371/journal.pone.0150101.t002

###### Routine chemistry biomarkers in patients with *MECP2* duplication syndrome, Rett syndrome, and control subjects.

![](pone.0150101.t002){#pone.0150101.t002g}

                              *MECP2* duplication syndrome (n = 5)[\*](#t002fn004){ref-type="table-fn"}   Rett syndrome (n = 24)   Control subjects (n = 12)   ANOVA P value
  --------------------------- --------------------------------------------------------------------------- ------------------------ --------------------------- ---------------
  Total cholesterol (mg/dl)   141.8 ± 39.80                                                               172.6 ± 27.3             144.6 ± 16.0                **0.007**
  ESR (mm/h)                  30.4 ± 21.43                                                                32.68 ± 15.58            9.16 ± 5.85                 **\<0.001**
  ALC (cells x10^3^/mm^3^)    3.32 ± 2.04                                                                 3.8 ± 0.85               2.68 ± 0.62                 **0.019**
  AMC (cells x10^3^/mm^3^)    0.394 ± 0.21                                                                0.737 ± 0.37             0.55 ± 0.15                 0.052
  Fibrinogen (mg/dl)          332.2 ± 90.8                                                                404.2 ± 92.1             334.7 ± 60.78               0.055
  Triglycerides (mg/dl)       89.2 ± 27.29                                                                66.5 ± 15.26             67.8 ± 28.47                0.111
  IgA (mg/dl)                 201.0 ± 157                                                                 117.2 ± 33.4             140.9 ± 34.1                0.101

Values were expressed as means ± standard deviation. The P value are referred to one-way ANOVA tests. Significant P values are highlighted in bold. Non-significant trends for AMC, fibrinogen, triglycerides, and IgA were evidenced.

High density lipoproteins-cholesterol, white blood cells, absolute counts for neutrophils, eosinophils, and basophils were not significant different in a comparison among the three examined populations.

ESR, erythrocyte sedimentation rate; ALC, absolute lymphocytes counts, AMC, absolute monocytes counts, IgA, immunoglobulin class A; mm, millimeter; h, hour.

\* data for patient \#6 were not available

Discussion {#sec010}
==========

Enhanced OS has been claimed to be involved in several pathological processes \[[@pone.0150101.ref035]\], including RTT, a rare genetic disease in which a deficiency of MeCP2 is demonstrated \[[@pone.0150101.ref036], [@pone.0150101.ref037]\]. In particular, we have previously shown that OS in brains of mice with *MECP*2 loss-of-function mutations takes place and can be rescued, along with neurological signs, by *Mecp2* brain specific gene reactivation \[[@pone.0150101.ref019]\]. However, to date, no hints on the opposite being true exist, *i*.*e*., no evidence is available for supporting the paradoxical concept that "too much" MeCP2 could lead to similar biochemical events as observed in conditions of "too little" MeCP2.

In the present study, we demonstrate, for the first time, the occurrence of a redox imbalance in patients with *MECP2* overexpression. Moreover, our data, while adding new evidence with regard to the *MECP2*-OS link, suggest that a fine tuning of the *MECP2* dosage may play a key role in regulating redox homeostasis in humans.

Whether mitochondria would be the main, or the only major, intracellular sources for the abnormal redox status in MDS and RTT is still to be ascertained \[[@pone.0150101.ref019], [@pone.0150101.ref038]--[@pone.0150101.ref041]\]. To this regard, an ultrastructural analysis of primary cultures of skin fibroblasts from RTT patients has shown no major morphological changes in the mitochondria \[[@pone.0150101.ref042]\]. At the same time, to the best of our knowledge, no studies on mitochondrial function in MDS have been published to date.

Oxidized products from polyunsaturated fatty acids appear to be promising molecules to be investigated in MDS, as they could mirror an ongoing oxidative brain damage. To this regard, in RTT mouse models, the presence of isoprostanes was evidenced in brain concomitant to elevated isoprostane plasma levels \[[@pone.0150101.ref019]\]. The reason for the strongly increased F~2~-IsoPs plasma levels in patients presenting *MECP2* gain-of-function mutations remains to be elucidated. Nevertheless, the evidenced dose-effect relationship between Xq28 duplication size and F~2~-IsoPs production further supports the existence of a close link between *MECP2* and redox homeostasis control. A close link between *MECP2* gene expression and F~2~-IsoPs formation has been reported in RTT where the *MECP2* mutations associated to more severe phenotypes exhibited higher F~2~-IsoPs plasma levels \[[@pone.0150101.ref017]\].

Interestingly, increased F~4~-NeuroP plasma levels in both MDS and RTT ([Fig 2](#pone.0150101.g002){ref-type="fig"}), suggest the involvement of the gray matter oxidative damage in both conditions. Currently, F~4~-NeuroPs are investigated as potential biomarker for neurological disease. In human RTT, F~4~-NeuroPs has been related to neurological symptoms severity, mutation type and clinical presentation \[[@pone.0150101.ref027]\], whereas their levels were significantly elevated in the brain of RTT symptomatic null mice \[[@pone.0150101.ref019]\]. The relevance of F~4~-NeuroPs in the neurological disease is also reported for the pathogenesis of Alzheimer's disease \[[@pone.0150101.ref043], [@pone.0150101.ref044]\].

Gain-of-function and loss-of-function *MECP2* mutations were found to generate distinct F~2~-dihomo-IsoPs patterns, oxidized fatty acid products considered as biomarkers of free radical damage to myelin \[[@pone.0150101.ref028], [@pone.0150101.ref045]\]. Although a reduced volume of the brain white matter has been recently reported in patients affected by Xq28 duplication involving the *MECP2* gene \[[@pone.0150101.ref046]\], our data might suggest a differential involvement of the brain white matter damage for RTT and MDS, on the base of the recovered F~2~-dihomo-IsoPs plasma levels.

This peculiar OS markers pattern further reinforces the specificity of the *MECP2*-OS link, which, far from being an epiphenomenon, appears to be intimately related to the specific *MECP2*-related disorders \[[@pone.0150101.ref017]\]. For some of those molecules known to be implicated in the general regulation of the redox homeostasis, an epigenetic modulation by MeCP2 has already been demonstrated \[[@pone.0150101.ref020]\]. To this regard, a possible role for contiguous genes to *MECP2*, *i*.*e*., *IRAK1* (OMIM \*300283), cannot be ruled out, as a compensatory upregulation of *IRAK1* has been reported in *Mecp2* loss-of-function mutations associated with experimental RTT murine models \[[@pone.0150101.ref047], [@pone.0150101.ref048]\].

Given that MDS and RTT both lead to severe neurodevelopmental disorders sharing several similar features ([Table 3](#pone.0150101.t003){ref-type="table"}), our data, beyond stressing the critical role of the *MECP2* function for the OS status, shed further light on the relevance of redox homeostasis in the central nervous system integrity.

10.1371/journal.pone.0150101.t003

###### Commonalities and differences between *MECP2* duplication syndrome and Rett syndrome.

![](pone.0150101.t003){#pone.0150101.t003g}

                                                          *MECP2* duplication syndrome                 Rett syndrome
  ------------------------------------------------------- -------------------------------------------- --------------------------------------------
  MeCP2                                                   ↑                                            ↓
  Irak1                                                   ↑                                            ↑/(↓ in deletions)
  p-NPBI                                                  ↑ [\*\*](#t003fn002){ref-type="table-fn"}    ↑ [\*](#t003fn002){ref-type="table-fn"}
  F~2~-IsoPs                                              ↑[\*\*\*](#t003fn002){ref-type="table-fn"}   ↑ [\*\*](#t003fn002){ref-type="table-fn"}
  F~2~-dihomo-IsoPs (supposed white matter involvement)   ↔ / ↑[\*](#t003fn002){ref-type="table-fn"}   ↑[\*\*\*](#t003fn002){ref-type="table-fn"}
  F~4~-NeuroPs (supposed gray matter involvement)         ↑[\*\*\*](#t003fn002){ref-type="table-fn"}   ↑[\*\*\*](#t003fn002){ref-type="table-fn"}
  IE-NPBI                                                 ↑[•](#t003fn002){ref-type="table-fn"}        ↑[•](#t003fn002){ref-type="table-fn"}
  Inflammation                                            Yes                                          Yes
  Gender                                                  Male/Female                                  Female
  Microcephaly                                            Yes (83.3%)                                  Yes
  Hand stereotypies                                       Yes (83.3%)                                  Yes (+++)
  Abnormal breathing                                      Yes (66.6%)                                  Yes (+++)
  Bruxism                                                 Yes (83.3%)                                  Yes (+++)
  Laryngomalacia                                          Yes (16.6%)                                  No
  Sleep disturbances                                      Yes (100%)                                   Yes (+++)
  Gastro esophageal reflux disease (GERD), drooling       Yes (100%)                                   Yes
  Constipation                                            Yes (100%)                                   Yes
  Genital abnormalities                                   Yes (16.6%)                                  No
  Facial dysmorphism                                      Yes (83.3%)                                  No
  Facial hypotonia                                        Yes (100%)                                   No
  Dysphagia                                               Yes (83.3%)                                  Yes
  Intellectual disability                                 Yes (100%)                                   Yes
  Developmental regression                                Yes (100%)                                   Yes
  Epilepsy                                                Yes (83.3%)                                  Yes
  Magnetic resonance imaging (MRI) abnormalities          Yes (100%)                                   Rare
  Hypotonia/ spasticity                                   Yes (100%)                                   Yes
  Feeding difficulties                                    Yes (100%)                                   Yes
  Recurrent Infections                                    Yes (66.6%)                                  Yes/No
  Endocrine abnormalities                                 Yes (16.6%)                                  Yes/No
  Hypoxia                                                 Not evaluated                                Yes (mild chronic)

↑, ↓, and ↔ indicate increased, decreased and similar levels, as compared to control subjects, respectively. Yes (+++) indicated high relevance of the clinical presentation, respectively.

•, \*, \*\*, \*\*\*, indicate \<100, 100--250, 250--500, and \>500 percentage increase, respectively. p-NPBI, plasma non protein bound; IE-NPBI, intraerythrocyte non protein bound iron; F~2~-IsoPs, F~2~-isoprostanes; F~4~-NeuroPs, F~4~-neuroprostanes; F~2~-dihomo-isoPs, F~2~-dihomo-isoprostanes

Alike RTT, MDS seems to elicit an inflammatory response. This condition could be linked to either imbalanced gene control or abnormal redox status. Although recurrent infections are a quite common feature of MDS \[[@pone.0150101.ref049]\], present in the clinical history of five out of our six patients, no signs of ongoing infection were detectable at the time of the blood sampling. However, it is also possible that the elevated ESR values are not directly related to the underlying genetic abnormality. Nevertheless, the inflammatory similarities observed in MDS and RTT well comply with the potential role for MeCP2 in regulating cytokine-dependent T helper cell differentiation \[[@pone.0150101.ref020]\]. Thus, *MECP*2 seems to exert a finely tuned regulation of major biological processes.

Conclusion {#sec011}
==========

Taken together, our data indicate that a *MECP2* disequilibrium, either due to loss-of-function or gain-of-function mutation, leads to similar phenotypes in terms of OS status, thus adding new evidence on the relationship between OS and *MECP2*.
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